Faculty profile

Stephen Welch

ResearcherClinical PharmacologyWestern University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Western University directory, so their courses may be missing. Find their university profile.

Stephen Welch

Researcher

Clinical Pharmacology

Health Sciences

Western University

London, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
27 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2020.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

709

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their Western University profile.

Clinical Pharmacology Drug Interactions Drug Metabolism Pharmacogenetics Pharmacogenomics

Latest papers

Health Care Impact of Comprehensive Genomic Profiling of Solid Tumors in Patient Management Using POWER (Precision Oncology at Western University).
The Journal of molecular diagnostics : JMD · 2026
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026
Analyzing the effect of neoadjuvant stereotactic ablative body radiotherapy on pancreatic tumor perfusion using computed tomography perfusion.
Frontiers in oncology · 2026

All 51 publications

Latest funding

Tumour cell reprogramming in pancreatic ductal adenocarcinoma as a means for therapeutic resistance
CIHR · 2022 · Co-investigator
$100,000
Integrated Precision Medicine Technology and Approach for Optimal Drug Therapy for Canadians
CIHR · 2020 · Principal investigator
$1,995,001
Metabolomics for prediction of cisplatin mediated acute kidney injury: a Canadian multi-centre adult and pediatric study
CIHR · 2019 · Co-investigator
$1,373,176

All 3 grants and awards

51 publications.

Health Care Impact of Comprehensive Genomic Profiling of Solid Tumors in Patient Management Using POWER (Precision Oncology at Western University).

Bhai P, Turowec JP, Pickard LA, Haghshenas S, Karim K, McConkey H, Santos S, Kerkhof J, Black M, Breadner D, Cecchini M, Howlett C, Schenkel L, Lalonde E, Panuganty V, Raphael J, Lohmann AE, Winquist E, Lenehan J, Stewart P, Tsvetkova E, Vincent M, Fernandes R, Bauman G, Welch S, Sadikovic B

The Journal of molecular diagnostics : JMD2026

DOI: 10.1016/j.jmoldx.2025.12.007 PMID: 41654253

Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.

Corbaux P, You B, Kagimura T, Glasspool RM, McNeish I, Cook A, Mirza MR, Lindemann K, Tinker AV, Welch S, Ray-Coquard IL, Subtil F, Colomban O, Péron J, Karamouza E, Kelly C, Lewsley LA, Paoletti X, Yanaihara N

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2026

DOI: 10.1016/j.ijgc.2025.102719 PMID: 41259844

Analyzing the effect of neoadjuvant stereotactic ablative body radiotherapy on pancreatic tumor perfusion using computed tomography perfusion.

Bang JY, Breadner D, Nguyen T, Skaro A, Goodman C, Welch S, Tsvetkova E, Lenehan J, Leslie K, Tang E, Quan D, Sey M, Yan B, Porplycia D, Sinfield J, Gaede S, Lee TY

Frontiers in oncology2026

DOI: 10.3389/fonc.2026.1677923 PMID: 41907609

Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis.

Corbaux P, You B, McNeish I, Welch S, Tinker AV, Mirza MR, Lindemann K, Kagimura T, Ray-Coquard IL, Subtil F, Péron J, Carty K, Kelly C, Colomban O, Karamouza E, Cook A, Paoletti X, Glasspool RM, Yanaihara N

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2026

DOI: 10.1016/j.ijgc.2026.104805 PMID: 42425044

Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Topham JT, Beckmann HM, Karasinska JM, Loree JM, Knox JJ, Kavan P, Jonker D, Welch S, Couture F, Lemay F

Clinical Cancer Research2026

DOI: 10.1158/1078-0432.ccr-26-0793

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma

Renouf DJ, Topham JT, Loree JM, Schaeffer DF, Knox JJ, Kavan P, Jonker D, Welch S, Couture F, Lemay F

Nature Communications2026

DOI: 10.1038/s41467-026-70120-z

Evolution in the diagnosis and treatment of carcinoma of unknown primary: a multicenter Canadian analysis.

Wong B, Liu J, Yeo S, Akurang D, Lo A, Xu YH, Wang Y, Welch S, Wheatley-Price P

The oncologist2025

DOI: 10.1093/oncolo/oyae298 PMID: 39520389

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, Lokich E, Kavecansky J, Leath CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Baghdadi TA, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C

Nature medicine2025

DOI: 10.1038/s41591-025-03566-1 PMID: 40044930

Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres.

Nair G, Black M, Baer K, Welch S, Laidley DT, Goodwin R, Leung M, Phillips WJ, Vickers M, Asmis T, Marginean H, Tsvetkova E

Current oncology (Toronto, Ont.)2025

DOI: 10.3390/curroncol32020086 PMID: 39996886

Is the Medical Oncology Workforce in Canada in Jeopardy? Findings from the Canadian Association of Medical Oncologists' COVID-19 Impact Survey Series.

Jones L, Colwell B, Hao D, Welch S, Campbell A, Gill S

Current oncology (Toronto, Ont.)2024

DOI: 10.3390/curroncol31080319 PMID: 39195302

Something wrong or missing on this profile? Suggest a correction

Stephen Welch

Research

Latest papers

Latest funding

Health Care Impact of Comprehensive Genomic Profiling of Solid Tumors in Patient Management Using POWER (Precision Oncology at Western University).

Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.

Analyzing the effect of neoadjuvant stereotactic ablative body radiotherapy on pancreatic tumor perfusion using computed tomography perfusion.

Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis.

Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma

Evolution in the diagnosis and treatment of carcinoma of unknown primary: a multicenter Canadian analysis.

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres.

Is the Medical Oncology Workforce in Canada in Jeopardy? Findings from the Canadian Association of Medical Oncologists' COVID-19 Impact Survey Series.

Tumour cell reprogramming in pancreatic ductal adenocarcinoma as a means for therapeutic resistance

Integrated Precision Medicine Technology and Approach for Optimal Drug Therapy for Canadians

Metabolomics for prediction of cisplatin mediated acute kidney injury: a Canadian multi-centre adult and pediatric study

Frequent collaborators

Lisa Wang

Stephanie Lheureux

Eric Winquist

Derek Jonker

Brandon Meyers

Holger Hirte

Yun-Hee Choi

Bekim Sadikovic

Steven Gallinger

Tracy Stockley

Edward Yu

Anton Skaro

Ephraim Tang

Matthew Cecchini

Christopher Howlett

Erin Kennedy

Anna Tinker

Ming-Sound Tsao

Lucy Gilbert

Rakesh Goel

Amit Oza

Xuan Li

Ying Wang

Alejandro Lazo-Langner

Helen Ettler

Monique Bertrand

Jacob McGee

Robin Mcleod

Neesha Dhani

Laurie Elit

Stewart Gaede

Wanrudee Isaranuwatchai

Conrad Falkson

Faiyaz Notta

Aaron Pollett

Ting-Yim Lee

Josee-Lyne Ethier

Michael Zappitelli

Simron Singh

Glenn Bauman